Drug - Juxtapid [Aegerion Pharmaceuticals, Inc.]
June 2013
Therapeutic area - Cardiovascular
JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
MHCP Provider Call Center 651-431-2700 or 800-366-5411